



ASX ANNOUNCEMENT

Cann Settles Legal Dispute with Rua Biosciences

4 June 2025 – Cann Group Limited (“Cann” or the “Company”) today announced that it has settled its legal dispute with Rua Biosciences Limited (NZX:RUA) (“Rua”). This follows Cann’s previous announcement on 16 February 2024 regarding legal proceedings initiated by Rua against Cannoperations Pty Ltd, a wholly owned subsidiary of Cann Group Limited.

Cann and Rua have entered into a confidential deed of settlement and release, which includes:

- a mutual release from any and all claims related to the dispute; and
- entry into two commercial agreements for Cann to supply certain medicinal cannabis products to Rua, intended for distribution in Australia and New Zealand, under agreed market-standard commercial terms.

There were no monetary payments made to either party under this settlement.

The settlement resolves the dispute and establishes a new commercial relationship between the parties moving forward.

Authorised for release by the Company Secretary, Cann Group Limited.

For all other information please contact:

Jenni Pilcher
CEO & Managing Director
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Steven Notaro
Company Secretary
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouponlimited.com | www.satipharm.com